Rheumatic Diseases
Disorders of connective tissue, especially the joints and related structures, characterized by inflammation, degeneration, or metabolic derangement.
Subtype terms (8)
More specific conditions that are subtypes of Rheumatic Diseases in the MeSH hierarchy.
- Arthritis, Juvenile
95 drugs (71 approved, 24 experimental)
- Arthritis, Rheumatoid
638 drugs (246 approved, 392 experimental)
- Fibromyalgia
141 drugs (86 approved, 55 experimental)
- Gout
114 drugs (68 approved, 46 experimental)
- Hyperostosis, Sternocostoclavicular
- Osteoarthritis
351 drugs (156 approved, 195 experimental)
- Polymyalgia Rheumatica
23 drugs (20 approved, 3 experimental)
- Rheumatic Fever
16 drugs (8 approved, 8 experimental)
Drugs by status
Approved for this indication (4)
Phase 4 trials (11)
Phase 3 trials (3)
Phase 2 trials (34)
- secukinumab
- urea
- bimekizumab
- canakinumab
- certolizumab pegol
- golimumab
- tofacitinib
- etanercept
- fab-fragment of anti-human cd4
- tacrolimus
- guselkumab
- hydroxychloroquine
- ixekizumab
- adalimumab
- risankizumab
- belimumab
- cyclosporine
- mycophenolate
- leflunomide
- sulfasalazine
- tocilizumab
- ustekinumab
- autologous bone marrow derived mesenchymal cells
- infliximab
- upadacitinib
- rituximab
- morphine
- azathioprine
- anakinra
- difelikefalin
- +4 more
Phase 1 trials (2)
Organizations
Organization Involved with Phase 4 Indications (11)
Organization Involved with Phase 3 Indications (14)
Organization Involved with Phase 2 Indications (18)
- Biotectid GmbH
- University of Leipzig
- Assiut University
- Stony Brook University
- Tel Aviv University
- University of Colorado, Denver
- Cara Therapeutics
- University of North Carolina at Chapel Hill
- Humboldt University
- Technical University of Dresden
- Children's National Medical Center
- University of Colorado
- Thrasher Research Fund
- Murdoch University
- University of Rennes
- Gift of Life International
- Karp Family Foundation
- The Uganda Heart Institute
Organization Involved with Phase 1 Indications (7)
Organization Involved with Other Experimental Indications (5)